{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:05:12Z","timestamp":1788109512778,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson Services Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euroneuro.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T08:37:58Z","timestamp":1744619878000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study"],"prefix":"10.1016","volume":"95","author":[{"given":"Mark E.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3418-0095","authenticated-orcid":false,"given":"John A.","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Kezic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1516-1125","authenticated-orcid":false,"given":"Mahesh N.","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Bleys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Dallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Salvadore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C.","family":"Drevets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.03.007_bib0001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0924-9338(97)86748-X","article-title":"DSM-IH-R Psychotic disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI","volume":"13","author":"Amorim","year":"1998","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0002","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fphar.2017.00357","article-title":"Evaluation of JNJ-54717793 a novel brain penetrant selective orexin 1 receptor antagonist in two rat models of panic attack provocation","volume":"8","author":"Bonaventure","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0003","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1124\/jpet.114.220392","article-title":"A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects","volume":"352","author":"Bonaventure","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1755-5949.2009.00102.x","article-title":"RESEARCH: validation of the Massachusetts General Hospital antidepressant treatment history questionnaire (ATRQ)","volume":"16","author":"Chandler","year":"2010","journal-title":"CNS. Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jad.2008.05.023","article-title":"Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder","volume":"113","author":"Fava","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/YCO.0000000000000376","article-title":"Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome","volume":"31","author":"Gaspersz","year":"2018","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0008","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1038\/npp.2013.109","article-title":"Differential effect of orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor Yohimbine","volume":"38","author":"Gozzi","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0009","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.neuroscience.2017.02.038","article-title":"Orexin 2 receptor regulation of the hypothalamic\u2013pituitary\u2013adrenal (HPA) response to acute and repeated stress","volume":"348","author":"Grafe","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0011","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0012","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.physbeh.2013.10.005","article-title":"Optogenetic examination identifies a context-specific role for orexins\/hypocretins in anxiety-related behavior","volume":"130","author":"Heydendael","year":"2014","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40120-023-00469-6","article-title":"Anxiety symptoms in patients with major depressive disorder: commentary on prevalence and clinical implications","volume":"12","author":"Hopwood","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0014","doi-asserted-by":"crossref","first-page":"e932","DOI":"10.4088\/JCP.14m09049","article-title":"Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine","volume":"75","author":"Ionescu","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0015","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/npp.2012.38","article-title":"Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia","volume":"37","author":"Johnson","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0017","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2016.01.009","article-title":"Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI\/SNRI in anxious depression","volume":"67","author":"Kent","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0018","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0924-9338(97)83296-8","article-title":"The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI","volume":"12","author":"Lecrubier","year":"1997","journal-title":"European Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0019","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bph.12415","article-title":"The hypocretins\/orexins: integrators of multiple physiological functions","volume":"171","author":"Li","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0021","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrd3681-c1","article-title":"Statistical refocusing in the design of phase II trials offers promise of increased R&D productivity","volume":"13","author":"Lindborg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0022","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0023","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euroneuro.2024.12.005","article-title":"Predicting the past: the risks and rewards of post-hoc findings","volume":"92","author":"Oliva","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0024","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0025","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0026","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jpsychires.2018.05.006","article-title":"Anxious distress in depressed outpatients: prevalence, comorbidity, and incremental validity","volume":"103","author":"Rosellini","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0027","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-1781(86)90060-0","article-title":"The Inventory for Depressive Symptomatology (IDS): preliminary findings","volume":"18","author":"Rush","year":"1986","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1017\/S0033291700035558","article-title":"The Inventory of Depressive symptomatology (IDS): psychometric properties","volume":"26","author":"Rush","year":"1996","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0029","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-020-00937-9","article-title":"Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans","volume":"10","author":"Salvadore","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0030","doi-asserted-by":"crossref","first-page":"20260","DOI":"10.1073\/pnas.1320325110","article-title":"Orexin\/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus","volume":"110","author":"Sears","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2025.03.007_bib0031","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0032","first-page":"1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of Mental disorders","volume":"282","author":"Spitzer","year":"1999","journal-title":"Patient Health Questionnaire. JAMA"},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0033","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.euroneuro.2025.03.007_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.comppsych.2017.02.010","article-title":"Reliability and validity of the DSM-5 anxious distress specifier interview","volume":"76","author":"Zimmerman","year":"2017","journal-title":"Compr. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2500063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2500063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:42:02Z","timestamp":1762321322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X2500063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"alternative-id":["S0924977X2500063X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.03.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. and ECNP. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}